Plain-English translation of NCT07409181 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called can help people with moderate to severe systemic lupus erythematosus (SLE). About 405 adults will be randomly assigned to take one of four different doses of the medication or a placebo (a pill with no active medicine) for one year, while continuing their regular lupus treatments. Researchers will track how well the treatment works and whether it causes any unwanted side effects.
Systemic lupus erythematosus is a serious autoimmune disease that can damage multiple organs and significantly affect quality of life. This study aims to find out whether this medication could provide a better treatment option for people with moderate to severe lupus and to identify the most effective and safe dose.
You likely qualify if…
You likely don't qualify if…
You will visit the study clinic regularly over slightly more than one year. You will take a daily tablet (either the test medication or placebo) for 12 months while also continuing your regular lupus medicines. At each visit, doctors will check your health, run blood tests, and ask about any side effects or changes in your symptoms. The study team will compare results between the different dose groups and the placebo group to see which dose works best and is safest.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States